Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v15-EN | Version v14-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2023-10-04 | 2023-10-03 |
| Drug Identification Number | 02248416 | 02248416 |
| Brand name | FASTURTEC | FASTURTEC |
| Common or Proper name | FASTURTEC | FASTURTEC |
| Company Name | SANOFI-AVENTIS CANADA INC | SANOFI-AVENTIS CANADA INC |
| Ingredients | RASBURICASE | RASBURICASE |
| Strength(s) | 1.5MG | 1.5MG |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 3 vials | 3 vials |
| ATC code | V03AF | V03AF |
| ATC description | ALL OTHER THERAPEUTIC PRODUCTS | ALL OTHER THERAPEUTIC PRODUCTS |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2023-05-26 | 2023-05-26 |
| Actual start date | 2023-05-25 | 2023-05-25 |
| Estimated end date | 2023-09-29 | 2023-09-29 |
| Actual end date | 2023-10-03 | 2023-10-03 |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Health Canada has allowed the temporary importation and distribution of Great Britain –labelled product. Lot No. 3J1011, Expiry Date:28.02.2026, PLGB 04425/0821 Please contact LAVALCS@sanofi.com in case of questions. | Health Canada has allowed the temporary importation and distribution of Great Britain –labelled product. Lot No. 3J1011, Expiry Date:28.02.2026, PLGB 04425/0821 Please contact LAVALCS@sanofi.com in case of questions. |
| Health Canada comments |